← All trials
NCT05944926
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2024
- Primary completion
- Aug 30, 2025
- Completion date
- Dec 30, 2026
- First posted
- Jul 13, 2023
- Last posted
- Nov 24, 2023
- Enrollment
- 1500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- All India Institute of Medical SciencesCollaborator
- Harvard UniversityCollaborator
- University of TorontoCollaborator
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityCollaborator
- Harvard UniversityCollaborator
- National Institute of Mental Health (NIMH)Collaborator
- SangathCollaborator
- Vanderbilt UniversityCollaborator
- Harvard UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.